THERAPY DOSSIER · th-a92b1da62235

AG1478 and compound 451

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28460454 ↗2017Reported benefit

Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats.

RatEndotoxin/LPSSprague-Dawleyn = 48 rats, 8 per group across six groupsIntragastric, oral20 mg/kg body weight in 0.5 per cent carboxymethylcellulose…Pretreatment for 7 consecutive days before intratracheal lipopolysaccharide

Model: Acute lung injury induced by a single intratracheal instillation of lipopolysaccharide 5 mg/kg in 0.9 per cent saline, assessed 24 hours later

Oral pretreatment with either epidermal growth factor receptor inhibitor reduced lung injury score, oedema, inflammatory cell influx, myeloperoxidase and inflammatory gene expression, with compound 451 more potent than AG1478.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…